ABBV-101 — Investigational Agent
BTK Degrader · Phase 1 · AbbVie
Mechanism of Action
Oral BTK-targeting degrader that recruits an E3 ubiquitin ligase to drive proteasomal degradation of Bruton tyrosine kinase, eliminating both scaffolding and kinase functions and retaining activity against BTK resistance mutations that impair inhibitors.
Investigational Indications
- Relapsed/refractory B-cell malignancies
- Chronic lymphocytic leukemia
- Non-Hodgkin lymphoma